Campbell & CO Investment Adviser LLC Takes $4.94 Million Position in Penumbra, Inc. $PEN

Campbell & CO Investment Adviser LLC acquired a new position in shares of Penumbra, Inc. (NYSE:PEN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 19,233 shares of the company’s stock, valued at approximately $4,936,000.

Several other large investors have also recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its stake in shares of Penumbra by 70.2% during the second quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after purchasing an additional 66 shares in the last quarter. AlphaQuest LLC bought a new position in Penumbra in the 1st quarter valued at approximately $66,000. Caitong International Asset Management Co. Ltd acquired a new stake in Penumbra during the 1st quarter worth approximately $76,000. Spire Wealth Management bought a new stake in Penumbra during the 2nd quarter worth approximately $91,000. Finally, Meeder Asset Management Inc. increased its position in Penumbra by 1,966.7% in the 1st quarter. Meeder Asset Management Inc. now owns 372 shares of the company’s stock valued at $99,000 after acquiring an additional 354 shares during the period. 88.88% of the stock is currently owned by institutional investors.

Penumbra Stock Performance

PEN stock opened at $266.25 on Friday. The firm has a market cap of $10.43 billion, a PE ratio of 70.81, a price-to-earnings-growth ratio of 2.10 and a beta of 0.51. The company has a current ratio of 6.75, a quick ratio of 4.04 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average price of $255.94 and a 200-day moving average price of $258.50. Penumbra, Inc. has a 1-year low of $221.26 and a 1-year high of $310.00.

Penumbra (NYSE:PEN) last announced its earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.90 by $0.07. The company had revenue of $354.69 million for the quarter, compared to analyst estimates of $340.77 million. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.85 EPS. Penumbra has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on PEN shares. Morgan Stanley lifted their price target on shares of Penumbra from $260.00 to $266.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. William Blair raised Penumbra to a “strong-buy” rating in a research report on Friday, July 18th. Royal Bank Of Canada reduced their price target on Penumbra from $330.00 to $325.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 30th. Robert W. Baird increased their price target on Penumbra from $283.00 to $285.00 and gave the company an “outperform” rating in a research note on Wednesday, July 30th. Finally, Wall Street Zen downgraded Penumbra from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $305.69.

Insider Activity at Penumbra

In other news, CEO Adam Elsesser sold 15,800 shares of Penumbra stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $269.65, for a total value of $4,260,470.00. Following the completion of the sale, the chief executive officer owned 182,460 shares in the company, valued at $49,200,339. The trade was a 7.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Harpreet Grewal sold 186 shares of the stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $227.58, for a total transaction of $42,329.88. Following the transaction, the director directly owned 8,516 shares in the company, valued at approximately $1,938,071.28. This represents a 2.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 48,802 shares of company stock worth $12,588,928. Corporate insiders own 4.20% of the company’s stock.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.